News

Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)
Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® ...
The Pharma Letter9h
Celltrion debuts its denosumab biosimilars in USA
The US subsidiary of South Korea-based Celltrion today announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo) ...
ascopubs.org2d
Getting a Grip on Aromatase Inhibitor–Associated Arthralgias
In 2004, the American Society of Clinical Oncology reported its evaluation of the use of aromatase inhibitors (AIs) in the adjuvant treatment of postmenopausal breast cancer. While the panel endorsed ...
Contract Pharma10h
Celltrion USA Launches Denosumab Biosimilars in the U.S.
Celltrion USA announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo), biosimilars referencing Prolia ...